Core Viewpoint - The company held a Q3 2025 performance briefing on October 24, 2025, to discuss its operational performance and address investor concerns [1] Group 1: Company Performance and Strategy - The company's respiratory medication revenue has decreased by nearly 60% year-on-year due to industry factors, prompting a strategic focus on expanding market coverage and enhancing brand awareness for key products [2] - The company has successfully expanded its pediatric cough syrup's market presence, covering over 2,000 public medical institutions, with significant progress in adult indications research [2] - The management plans to accelerate the development of innovative traditional Chinese medicine (TCM) products, aiming to establish a product matrix with annual sales of 300-500 million yuan for multiple products [3][4] Group 2: Product Development and Market Position - The company has received approval for its blood-nourishing pain relief granules but has not yet launched them in hospitals; it plans to consider OTC status for easier access [5] - The company is focusing on chronic disease areas such as orthopedics and cardiovascular health, with several innovative TCM projects in the pipeline, including clinical trials for various products [5] - The company aims to leverage historical opportunities in TCM development to enhance market coverage and brand building, fostering new profit growth points [5]

Core Insights - JD Health and Hansoh Pharmaceutical are deepening their collaboration, with Hansoh's new pulmonary hypertension drug, Silapad, set for exclusive online launch on JD Health's platform [1][3] - The partnership aims to enhance drug accessibility for pulmonary hypertension patients and leverage JD Health's channel advantages for market coverage [1][3] Summary by Sections Collaboration Details - The collaboration will expand into multiple fields, including anti-infection and respiratory health, with JD Health enhancing patient medication adherence through professional services [3] - In the second half of 2025, Hansoh will deepen cooperation in metabolism and oncology areas on JD Health's platform [3] Product Launch and Services - Hansoh plans to launch more core products on JD's self-operated channels, prioritizing innovative drugs for exclusive online release [3] - The partnership will create a closed-loop service from online consultations to drug delivery, utilizing JD's internet hospital and pharmacy capabilities [3] Strategic Importance - Hansoh's collaboration with JD Health is a key part of its strategic transformation, aiming to manage the full cycle from product development to patient service [3] - Both companies emphasize the importance of patient needs and aim to improve the accessibility of innovative drugs and comprehensive health management solutions [3]